Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer.
locoregional control
medullary thyroid cancer
overall survival
postoperative radiation therapy
targeted therapy
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
revised:
28
10
2023
received:
09
08
2023
accepted:
14
11
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Use of postoperative radiation therapy (PORT) in locoregionally advanced medullary thyroid cancer (MTC) remains controversial. The objective was to evaluate the effect of PORT on locoregional control (LRC) and overall survival (OS). Retrospective cohort study of 346 MTC patients separated into PORT and no-PORT cohorts. Relative indications for PORT, as well as changes in patterns of treatment, were recorded. 49/346 (14%) received PORT. PORT was associated with worse OS; adjusted HR = 2.0 (95%CI 1.3-3.3). PORT was not associated with improved LRC, even when adjusting for advanced stage (Stage III p = 0.892; Stage IV p = 0.101). PORT and targeted therapy were not associated with improved OS compared to targeted therapy alone; adjusted HR = 1.2 (95%CI 0.3-4.1). Use of PORT in MTC has decreased and its indications have become more selective, coinciding with the advent of effective targeted therapies. Overall, PORT was not associated with improved LRC or OS.
Sections du résumé
BACKGROUND
BACKGROUND
Use of postoperative radiation therapy (PORT) in locoregionally advanced medullary thyroid cancer (MTC) remains controversial. The objective was to evaluate the effect of PORT on locoregional control (LRC) and overall survival (OS).
METHODS
METHODS
Retrospective cohort study of 346 MTC patients separated into PORT and no-PORT cohorts. Relative indications for PORT, as well as changes in patterns of treatment, were recorded.
RESULTS
RESULTS
49/346 (14%) received PORT. PORT was associated with worse OS; adjusted HR = 2.0 (95%CI 1.3-3.3). PORT was not associated with improved LRC, even when adjusting for advanced stage (Stage III p = 0.892; Stage IV p = 0.101). PORT and targeted therapy were not associated with improved OS compared to targeted therapy alone; adjusted HR = 1.2 (95%CI 0.3-4.1).
CONCLUSIONS
CONCLUSIONS
Use of PORT in MTC has decreased and its indications have become more selective, coinciding with the advent of effective targeted therapies. Overall, PORT was not associated with improved LRC or OS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol. 2010;102(2):175-178.
Jin M, Megwalu UC, Noel JE. External beam radiotherapy for medullary thyroid cancer following total or near-total thyroidectomy. Otolaryngol Head Neck Surg. 2021;164(1):97-103.
Ow TJ, Mehta V, Kim S, Vakil M, Friedmann P, In H. Evaluation of survival and postoperative radiation among patients with advanced medullary thyroid carcinoma: an analysis of the National Cancer Database. Ann Surg Oncol. 2022;29(4):2582-2591.
Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer-local disease control in the modern era. Head Neck. 2008;30(7):883-888.
Call JA, Caudill JS, McIver B, Foote RL. A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience. Rare Tumors. 2013;5(3):e37.
Groen AH, Beckham TH, Links TP, et al. Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. J Surg Oncol. 2019;121:234-243.
Brook I. Late side effects of radiation treatment for head and neck cancer. Radiat Oncol J. 2020;38(2):84-92.
FDA approves vandetanib for treatment of medullary thyroid cancer. Oncology Times, 2011;33(8):33.
FDA approves cometriq for metastatic medullary thyroid cancer. Oncology Times, 2012;34(24):27.
Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid. 1996;6(4):305-310.
Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40:1573-1604.
Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835.
Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491-501.
Jozaghi Y, Zafereo M, Williams MD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck. 2021;43(1):E7-E12.
Contrera KJ, Gule-Monroe M, Hu MI, et al. Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series. Thyroid. 2022;33(1):129-132.